Patent Examiner Robert H. Havlin
Art Unit 1626 · Heterocyclic Drug Compounds, Synthesis & Therapeutic Uses · Tech Center 1600 · 267 applications filed 2021–2026
Robert H. Havlin is a USPTO patent examiner in Art Unit 1626 (Heterocyclic Drug Compounds, Synthesis & Therapeutic Uses) with 267 applications from filing years 2021–2026. Examiner Havlin's allowance rate is 30.1%, below the 82.1% USPTO average for applications filed in the same years. The examiner ranks harder than 96% of examiners. In 2021, decided applications with an examiner interview were allowed 76.4 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1626 · Heterocyclic Drug Compounds, Synthesis & Therapeutic Uses
- Title / gradeSupervisory Patent Examiner · GS-15
- Service20 years
- PhoneOn each office action
- Email[email protected]
- In USPTO recordsHAVLIN, ROBERT H
Examiner Havlin can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Havlin
- The data favors an interview. Interviewed cases were allowed more often in both measured years, by 45.6 to 76.4 points.
- Plan for the timeline. First office action averages 774 days vs the 580-day USPTO norm.
- Expect a §103. Obviousness is the most-issued rejection (103), and applicants overcame it 39.1% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 4.0 to 45.6 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeApplicants overcame 18 of the 46 decided §103 obviousness rejections from Examiner Havlin in the data. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Havlin?
Draft your response with Examiner Havlin's record and Art Unit 1626's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response workflow.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 17.2% | 66.7% | 21.1% | +45.6pp |
| 2021 | 34.6% | 88.9% | 12.5% | +76.4pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Havlin.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 26.4% | 66.7% | 21.1% | +45.6pp |
| 2021 | 30.8% | 42.9% | 38.9% | +4.0pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/253704 | Triazine Dione Derivative, Preparation Method Therefor and Application Thereof in Medicine | Patented | 1 | 🔒 View |
| 18/173386 | Nucleic Acid Extraction and Amplification Controls and Methods of Use Thereof | Abandoned | 2 | 🔒 View |
| 18/001002 | Quinazoline Derivatives Useful as Selective HDAC6 Inhibitors | Patented | 2 | 🔒 View |
| 17/915608 | Methods and Pharmaceutical Compositions of Thromboxane A2 Receptor Antagonist for the Treatment of COVID-19 | Abandoned | 3 | 🔒 View |
Art Unit 1626 technology
Frequently asked questions
What is Examiner Robert H. Havlin's allowance rate?
Is Examiner Havlin a hard examiner?
Do examiner interviews help with Examiner Havlin?
What is Examiner Havlin's most common rejection?
Is an RCE worth filing with Examiner Havlin?
How long until the first office action from Examiner Havlin?
How do I contact Examiner Robert H. Havlin?
Put Examiner Havlin's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.